Health Condition 1: null- Idiopathic Polypoidal Choroidal Vasculopathy Health Condition 2: H36- Retinal disorders in diseases classified elsewhere
Conditions
Interventions
Intervention1: Micropulse with Intravitreal Injection: The does, frequency and total duration of therapy will depend on the disease progression during the coarse of study.
Duration is determined by SR
Sponsors
LV Prasad Eye Institute
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients of PCV who are treatment naïve or have received intra vitreal anti- VEGF injection (at least 6 months prior to being enrolled into the study). 2. Patients with best corrected visual acuity (BCVA) between 20/30 to 20/400.
Exclusion criteria
Exclusion criteria: 1. Patients not giving consent for study 2. Patients who received any form of laser treatment before enrolment into the study including: focal laser photocoagulation, vertiporfin PDT, trans pupillary thermotherapy. 3. Patients who received any intravitreal injection within a period of 6 months prior to the enrolment time. 4. Patients with significant cataract or corneal opacity. 5. Patients having reduced vision due to any other retinal pathology. 6. Patients allergic to fluorescein or Indocyanine green (ICG). 7. Patients with extra macular polyps.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. To determine the efficacy of micropulse laser in the treatment of PCVTimepoint: 12 months | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Proportion of patients achieving the polyp closure or regression (as described below) at the end of 12 months of enrolment into the study. 2. Number of Anti- VEGF injections injected intravitreally 3. Proportion of patients with no fluid on OCT. 4. Gain of visual acuity from baseline. Timepoint: 12 months | — |
Countries
India
Contacts
Public ContactCharitha
LV Prasad Eye Institute
Outcome results
None listed